2006
Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC)
Green M, Pusztai L, Theriault R, Adinin R, Hofweber M, Fukushima M, Mita A, Bindra N, Hortobagyi G. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). Journal Of Clinical Oncology 2006, 24: 10576-10576. DOI: 10.1200/jco.2006.24.18_suppl.10576.Peer-Reviewed Original ResearchMetastatic breast cancerPhase II doseBID days 1TAS-102Dose levelsBreast cancerDay 1Grade 3 non-hematologic toxicityEvaluable metastatic breast cancerInitial starting doseNon-hematologic toxicitiesInitial dose levelAdditional dose levelsHighest dose levelEvaluation of responseMinimal alopeciaHematologic toxicityStarting doseDaily dosingStandard therapyOral combinationStudy doseClinical activityOral administrationGrade 3
1998
Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer
Pusztai L, Walters R, Valero V, Theriault R, Hortobagyi G. Daily Oral Etoposide in Patients With Heavily Pretreated Metastatic Breast Cancer. American Journal Of Clinical Oncology 1998, 21: 442-446. PMID: 9781596, DOI: 10.1097/00000421-199810000-00004.Peer-Reviewed Original ResearchConceptsGrade 4 toxicityMetastatic breast cancerSignificant hematologic toxicityOral etoposideBreast cancerGrade 2Hematologic toxicityDaily oral etoposideFourth-line agentZubrod performance statusPercent of patientsPhase II studyMajority of patientsGreater thrombocytopeniaNeutropenic feverStable diseasePrevious therapyRadiologic evidenceII studyMedian durationPartial responsePerformance statusMedian ageMore regimensSevere anemia